TET2 and neoplasm: Moreover, VC therapy did not exert a significant impact on tumor vessel coverage by pericytes, intratumoral hypoxia levels, and CD8+ T cell infiltration in these tumors with Tet2 or Stat5a deficiency (Fig. 10e, Supplementary Fig. 12g).